Assessment of therapeutic effects of Ketamin in treatment of major depressio
- Conditions
- Condition 1: major depression. Condition 2: Major depression.Recurrent depressive disorder, current episode severe without psychotic symptomsSevere depressive episode without psychotic symptoms
- Registration Number
- IRCT201208159585N2
- Lead Sponsor
- Vice Chancellor for research of Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
all patients with MDD subjected to ECT who is validated by a psychiatric physician, age 18 – 50. Exclusion criteria: Ketamin contraindication, open eye injuries with high IOP, high ICP, intracranial tumors, tachycardia, high blood pressure, history of ischemic heart diseases, aneurism in main vessels, alcohol and drug consumption within last 3 months, history of Intracranial Hemorrhage(ICH),cardiovascular diseases, unstable medical illnesses, pregnancy, patients older or younger than mentioned age, weight more than 90Kg,allergy to Ketamin, hypo and hyperthyroidism, other mental disorders coexisted with MDD such as dementia and bipolar disorder, patients with pacemakers, patients without informed consent or their family are unreliable.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of depression. Timepoint: before starting, after second, 4th, 6th session of ECT. Method of measurement: Hamilton questionnaire.
- Secondary Outcome Measures
Name Time Method Blood pressure and heart rate. Timepoint: before induction, after ECT, 5, 10, 15 minutes later. Method of measurement: electronic monitoring device.;Duration of seizure. Timepoint: every session. Method of measurement: second.;Recovery time. Timepoint: after administration of anesthetic drugs until the patient's consciousness. Method of measurement: minute.